bioRxiv (Cold Spring Harbor Laboratory)
August 11, 2026
István Pesti, Ágnes Bessenyei, Rita Frank et al.
preprint
ABSTRACT N,N -dimethyltryptamine (DMT) is an endogenous psychedelic tryptamine that has recently emerged as a promising therapeutic candidate for acute ischemic stroke. Although DMT consistently reduces infarct size, attenuates neuroinflammation, and improves functional outcome in experimental stroke, the cellular and receptor mechanisms underlying these effects remain poorly understood....
International Journal of Whole Person Care
August 9, 2026
Houman Farzin
This presentation will review the history of scientific research into the use of psychedelic medicines for the treatment of existential distress due to life-threatening illnesses, it will then outline the current state of affairs in North America, and conclude with exploring the implications it will have on the future of palliative care. Despite the significant advances in the field of...
Psychological Medicine
August 7, 2026
Igor Branchi
Psychiatric disorders are complex conditions involving multifactorial, nonlinear causal dynamics, which make effective treatment challenging. To address this complexity, a framework is proposed that distinguishes between types of causality: permissive causality, which pertains to factors affecting the likelihood of an outcome occurring, and instructive causality, which refers to factors shaping...
British Journal of Clinical Pharmacology
August 7, 2026
J. Nadler, Michaela J. Sommer, Annette Zschiesche et al.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide), the N-ethyl derivative of LSD. An adolescent patient developed moderate to severe...
Quality in Sport
August 7, 2026
M. Lewczuk, Natalia Trędota, Zuzanna Czyżewicz et al.
Background: Cluster headache is a severely disabling headache disorder. Despite the availability of acute and preventive therapies, treatment efficacy remains incomplete, leaving many athletes and other patients with insufficient symptom control leading to decreased quality of life and performance. Increasing interest has emerged in psychedelic compounds, particularly psilocybin, as potential...
CNS Drugs
August 7, 2026
Chiranth Bhagavan, Olivia Carter, Glenn Nielsen et al.
BACKGROUND: Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers....
Asclepius International Journal of Scientific Health Science
August 7, 2026
Arthur Gomes Ferreira
A dependência da nicotina representa um dos principais desafios da saúde pública mundial, sendo responsável por elevadas taxas de morbimortalidade e associada ao desenvolvimento de doenças cardiovasculares, respiratórias e neoplásicas. Embora existam diferentes estratégias terapêuticas para a cessação do tabagismo, as elevadas taxas de recaída evidenciam a necessidade de novas abordagens...
npj Mental Health Research
August 6, 2026
Elliot Marseille, Hannes Kettner, Tyrone J. Sgambati et al.
Abstract Psychiatric trials typically define success as symptom reduction, yet patients prioritize meaning, vitality, and functioning. This imbalance undervalues experiential benefits, distorting clinical, policy, and FDA decisions. Psychedelic trials illustrate this, where robust well-being gains sometimes accompany modest symptom effects. We argue well-being should be elevated to co-primary...
Nature Medicine
August 6, 2026
James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al.
1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
Journal of Psychopharmacology
August 6, 2026
Tijmen Bostoen, Erwin Krediet, Annette van Schagen et al.
Background: The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT. Methods: Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in...